<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04760405</url>
  </required_header>
  <id_info>
    <org_study_id>2011190017</org_study_id>
    <nct_id>NCT04760405</nct_id>
  </id_info>
  <brief_title>The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple Myeloma</brief_title>
  <official_title>The TOTOM Trial: Tai Chi to Optimize Transplant Outcomes for Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Arizona</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current proposal aims to test the feasibility of immune function analysis for Tai Chi&#xD;
      Easy (TCE) intervention in multiple myeloma (MM) patients undergoing autologous stem cell&#xD;
      transplantation (ASCT) with concurrent exploration of health related quality of life (HRQOL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current proposal aims to test the feasibility of immune function analysis for TCE&#xD;
      intervention in MM patients undergoing ASCT with concurrent exploration of HRQOL. The data&#xD;
      obtained from this trial will provide supporting data for a future randomized clinical trial&#xD;
      evaluating the impact of TCE on immune function (incidence of ASCT related infectious&#xD;
      complications, natural killer cell phenotype and activity, and myeloma remission rate (clonal&#xD;
      plasma cell % at day 100, minimal residual disease (MRD)), with the evaluation of efficacy on&#xD;
      improving HRQOL during ASCT. Successful completion of this CROC project will provide&#xD;
      necessary data to support future grant applications, in particular the feasibility of&#xD;
      immunoassay evaluation of MM patients undergoing ASCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 11, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine natural killer cell phenotype</measure>
    <time_frame>Baseline</time_frame>
    <description>Determine natural killer (NK) phenotype through peripheral blood analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine natural killer cell phenotype</measure>
    <time_frame>Day 14</time_frame>
    <description>Determine natural killer (NK) phenotype through peripheral blood analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine natural killer cell phenotype</measure>
    <time_frame>Day 30</time_frame>
    <description>Determine natural killer (NK) phenotype through peripheral blood analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine natural killer cell phenotype</measure>
    <time_frame>Day 100</time_frame>
    <description>Determine natural killer (NK) phenotype through peripheral blood analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine NK cell activity</measure>
    <time_frame>At baseline</time_frame>
    <description>Determine NK cell activity through peripheral blood analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine NK cell activity</measure>
    <time_frame>Day 14</time_frame>
    <description>Determine NK cell activity through peripheral blood analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine NK cell activity</measure>
    <time_frame>Day 30</time_frame>
    <description>Determine NK cell activity through peripheral blood analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine NK cell activity</measure>
    <time_frame>Day 100</time_frame>
    <description>Determine NK cell activity through peripheral blood analysis</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine immune function</measure>
    <time_frame>At baseline</time_frame>
    <description>Determine immune function through peripheral blood analysis of immune factors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine immune function</measure>
    <time_frame>Day 14</time_frame>
    <description>Determine immune function through peripheral blood analysis of immune factors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine immune function</measure>
    <time_frame>Day 30</time_frame>
    <description>Determine immune function through peripheral blood analysis of immune factors</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Determine immune function</measure>
    <time_frame>Day 100</time_frame>
    <description>Determine immune function through peripheral blood analysis of immune factors</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple Myeloma</condition>
  <condition>Stem Cell Transplant Complications</condition>
  <arm_group>
    <arm_group_label>Tai Chi Easy Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tai Chi Easy: TCE is a standardized protocol used in several prior studies. TCE has been manualized and has a formal training program for instructors. The protocol is taught as a series of repeated and simple-to-learn movements. Patients will receive two 30-minute small group training sessions (Via Zoom) within 7 days of their scheduled transplant. After the training has been completed the participant will be provided with written (via manual) and electronic (DVD, MP3 file download) materials to continue with self-direct practice throughout the duration of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Tai Chi Easy</intervention_name>
    <description>Patients will receive two 30-minute small group training sessions (Via Zoom) within 7 days of their scheduled transplant. After the training has been completed the participant will be provided with written (via manual) and electronic (DVD, MP3 file download) materials to continue with self-direct practice throughout the duration of the study.</description>
    <arm_group_label>Tai Chi Easy Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosis of Multiple Myeloma planned to undergo bone marrow transplant&#xD;
&#xD;
          2. 18 years or older&#xD;
&#xD;
          3. English speaking&#xD;
&#xD;
          4. General proficiency to read/write in English&#xD;
&#xD;
          5. Able to attend TCE training session per study protocol&#xD;
&#xD;
          6. ECOG performance status 0-1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Currently performs Tai Chi, QiQong, or Yoga at least once weekly or more&#xD;
&#xD;
          2. Syncopal event in prior 60 days&#xD;
&#xD;
          3. Concurrent major depressive disorder or anxiety disorder (DSMIV)&#xD;
&#xD;
          4. Chronic dizziness or vestibular disorders&#xD;
&#xD;
          5. History of recurrent falls (&gt;2 in the prior year)&#xD;
&#xD;
          6. Grade 3 or greater neuropathy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kristinna Gowin, DO</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashley Larsen, MS</last_name>
    <phone>(520) 626-7761</phone>
    <email>golmana@email.arizona.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Arizona</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amy Selegue, BA, BSN, MLS</last_name>
      <phone>520-626-0301</phone>
      <email>aselegue@arizona.edu</email>
    </contact>
    <investigator>
      <last_name>Krisstina Gowin, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>January 15, 2021</study_first_submitted>
  <study_first_submitted_qc>February 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 18, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple Myeloma</keyword>
  <keyword>Stem cell transplant</keyword>
  <keyword>Autologous stem cell transplantation</keyword>
  <keyword>ASCT</keyword>
  <keyword>Tai Chi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

